IL1B and COVID-19: In the same way, in a recent study, it has been demonstrated that combination treatment with human monoclonal anti-IL-1β antibody, remdesivir, and steroids in moderate-to-severe hospitalized COVID-19 patients can reduce inflammatory markers [18].